logo
Wrong email address or username
Wrong email address or username
Incorrect verification code
back to top
Search tags: Drugs
Load new posts () and activity
Like Reblog Comment
text 2019-03-20 13:19
Cytotoxic Drugs Market Top-Vendor Offerings And Market By End-User Segments Forecasted Till 2026

Cytotoxic drugs or cytostatics (cytotoxic chemotherapy) are agents used to destroy cancer cells and tumors by inhibiting cell division. These drugs are widely used as anti-cancer agents and are used to boost the outcomes of surgery or radiotherapy, reduce metastasis, and diminish cancer symptoms. Increasing use and approval of cytotoxic drugs is the major factor driving the cytotoxic drugs market growth. These drugs are also used for their immunosuppressive effect in the treatment of auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection. Click To Read More On Cytotoxic Drugs Market


Global Cytotoxic Drugs Market: Drivers


The cytotoxic drugs market size is expected to grow significantly during the forecast timeframe, owing to increasing incidences of cancer worldwide. According to World Health Organization’s (WHO) 2018 report, around 9.6 million deaths were recorded due to cancer and around 18.1 million new cases of cancer were diagnosed in 2018 worldwide.


Furthermore, increasing number of cytotoxic drug approvals is expected to boost the market growth. For instance, in November 2018, the U.S. FDA approved Pfizer’s DAURISMO (glasdegib) in the U.S. for adult patients with newly-diagnosed acute myeloid leukemia for whom intensive chemotherapy is not an option. Other potential factor that contributes to cytotoxic drugs market revenue growth is increasing therapeutic area of cytotoxic drugs in auto-immune conditions, rheumatoid arthritis, psoriasis, or prevention of transplant rejection because of its immunosuppressive or anti–proliferative effects.


Global Cytotoxic Drugs Market: Restraints


The major restraining factor for the cytotoxic drugs market growth is adverse side effects shown by consumption of cytotoxic drugs such as nausea and vomiting, severe diarrhea, and damage to bone marrow. Cytotoxic drugs can be toxic to other organ systems and lead to conditions such as gastrointestinal toxicity, neurotoxicity renal toxicity, and cardiovascular toxicity. For instance, according to NHS Lothian Joint Formulary, drugs such as fluorouracil, doxorubicin, and oral capecitabine may cause severe stomatitis, diarrhea, and coronary spasm mimicking angina. Moreover, systemic anti-cancer therapy (SACT) drugs increase the risk of thromboembolic disease eventually restraining the cytotoxic drugs market growth.


Global Cytotoxic Drugs Market: Competitive Landscape


Key players operating in the global cytotoxic drugs market include, Eli Lilly and Company, Sanofi S.A., F. Hoffmann-La Roche Ltd, Pfizer Inc., Celgene Corporation, Amgen Inc., Novartis AG Merck and Co., Johnson and Johnson, and GlaxoSmithKline Plc.


Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2533


Global Cytotoxic Drugs Market: Regional Analysis


North America is expected to hold a dominant position in the cytotoxic drugs market over the forecast period, owing to increasing awareness and availability of wide range of cytotoxic drugs in the region. According to a study published in National Center for Biotechnology Information (NCBI) in 2017, the U.S. Food and Drug Administration has approved 61 cytotoxic drugs for cancer, which help in increasing the survival rates of cancer patients.


Asia Pacific cytotoxic drugs market size is expected to witness significant growth, owing to large patient base and increasing healthcare insurance schemes in the region. For instance, in 2018, the Government of India launched Pradhan Mantri Jan Arogya Yojana (PMJAY) to provide health insurance worth US$ 7,124.54 to over 100 million families, annually.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Like Reblog Comment
text 2019-03-15 10:07
Antibacterial Drugs Market To Witness Widespread Expansion During 2026

The Global Antibacterial Drugs Market size was valued at US$ 43,791.2 million in 2017, and is expected to exhibit a CAGR of 1.4% over the forecast period (2018 – 2026).


Antibacterial drugs are used in treatment or prohibition of bacterial infections caused due to various factors such as climatic changes, unhygienic lifestyle specially in emerging economies and others. Major challenge associated with antibacterial drugs is resistance of bacteria towards it. Significant studies are carried out to develop new antibacterial drugs to combat these problems.


Market Dynamics


Increasing prevalence of infectious diseases is a major factor driving antibacterial drugs market growth. According to World Health Organization (WHO), September 2018, annually around 11 million to 21 million cases of typhoid fever are reported worldwide. Moreover, growing geriatric population susceptible to high risk of bacterial infection, majorly caused due to age related changes in immunology is expected to boost the market growth. The Current Opinion in Microbiology Journal 2016, stated Lower respiratory tract infection (Pneumonia), as the most common cause of infection disease in older patients in the U.S. and estimated it as 6 leading cause of death in the U.S.


However, price control of antibacterial drugs, genetic mutation in aging population, and decrease in financial incentives has distracted the focus of pharmaceutical companies from research and development of antibacterial drugs. In September 2016, AstraZeneca announced an agreement with Pfizer to sell the development and commercialization rights to its late-stage small molecule antibiotics business as AstaZeneca does not find antibiotic research as major area for development in their business.


Increasing population and high incidences of infectious diseases in North America are expected to bolster the market growth


North America holds dominant position in the global antibacterial drugs market, owing to rising population base susceptible to infectious diseases and higher incidences of infectious diseases such as tuberculosis and others. According to the Centers for Disease Control and Prevention (CDC), in 2017, an estimated 9,105 patients were diagnosed with tuberculosis in the U.S.


Moreover, key players in the market are focused on receiving the U.S. Food and Drug Administration (FDA) approval for novel products to treat patients diagnosed with infectious diseases. For instance, in February 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Egaten, used for the treatment of Fascioliasis caused by Fasciola hepatica infection.


Key Players


Major players operating in the global antibacterial drugs market include Novartis AG, Allergan, Bristol Myers Squibb Company, AstraZeneca, Johnson and Johnson, Merck & Co., Inc., GlaxoSmithKline Plc. (GSK), Sanofi SA, Bayer AG, and Pfizer Inc.


Ask For Sample Copy Of This Business Research Report : 
https://www.coherentmarketinsights.com/insight/request-sample/177


Increasing incidences of infectious diseases is expected to propel growth of the antibacterial drugs market


Antibacterial drugs are used in treatment of infection caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others is expected to drive the market growth. According to the World Health Organization (WHO) November 2018 factsheet, an estimated 219 million people were diagnosed by malaria in 2017, in 19 countries.


Moreover, initiatives by government concerned to antibacterial resistance is expected to propel market growth over the forecast period. For instance, in May 2018, the UK government announced fund of US$ 34 million to fight against antimicrobial resistance (AMR). This funding will be distributed to the 4 projects such as Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator of US$ 23 million, Global Antibiotic Research and Development Partnership invested US$ 1 million, and US$ 5 million for two project such as bilateral partnership with Argentina and Foundation for Innovative New Diagnostics.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Like Reblog Comment
text 2019-03-11 11:29
Neurological Disorder Drugs Market Growth Prospects & Trends Recorded until 2026

Neurological disorder is associated with dysfunction in any part of the brain or nervous system, resulting in physical and/or psychological symptoms. Various neurological disorders are congenital, which emerge during the early years of embryo developmental and may be diagnosed at birth. Whereas, acquired neurological disorders develop after the birth due to traumatic brain injuries, immune disorders, postnatal injections, spinal cord injuries, neoplasm, and exposure to environmental chemicals or toxins, among others.

 

Many bacterial (Mycobacterial tuberculosis, Neisseria meningitides), viral (Human Immunodeficiency Virus (HIV), Enteroviruses, West Nile Virus, Zika), fungal (Cryptococcus, Aspergillus), and parasitic (malaria, Chagas) infections can also affect the nervous system, resulting in neurological disorders.

 

Ask For In-Depth Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/2363

 

Neurological Disorder Drugs Market: Drivers

 

Rising awareness associated with early disease diagnosis through awareness campaigns by government regulatory bodies and private organizations, and market entry of efficient drugs in the near future, owing to the presence of strong drug pipeline is expected to drive growth of the neurological disorder drugs market.

 

For instance, according to a report published by the Pharmaceutical Research and Manufacturers of America (PhRMA) in April 2018, there are currently 537 medicines in development by biopharmaceutical companies in the U.S for various neurological disorders. This mainly includes 95 medicines for brain tumors, 46 for chronic pain, and 92 for Alzheimer’s disease. The other 30 are being developed for a range of conditions including multiple sclerosis, migraines, amyotrophic lateral sclerosis, and Parkinson’s disease.

 

Neurological Disorder Drugs Market: Regional Analysis

 

North America is expected to hold a dominant position in the global neurological disorder drugs market and account for the largest market share over the forecast period, owing to high presence of key players in the region and approval and launch of novel products by them in the region.

 

For instance, in May 2018, Amgen received the U.S. FDA approval for Aimovig (erenumab-aooe), for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach and the only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which plays a critical role in migraine.

 

Neurological Disorder Drugs Market: Key Players

 

Key players operating in the global neurological disorder drugs market include Amgen Inc., UCB S.A., Neurocrine Biosciences, Inc., Pfizer Inc., Biogen Inc., Teva Pharmaceutical Industries Ltd., AcelRx Pharmaceuticals, Inc., Eli Lilly and Company, Ionis Pharmaceuticals, Inc., Adamas Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc., Otsuka America Pharmaceutical, Inc., AstraZeneca plc, and Novartis International AG.

 

Neurological Disorder Drugs Market: Taxonomy

 

The global neurological disorder drugs market is segmented on the basis of drug type, disease type, distribution channel, and region.

 

By Drug Type:

 

Antipsychotic

Antiepileptic

Anticholinergic

Analgesics

Hypnotic & Sedative

Anticoagulants

Antihypertensive

 

By Disease Type:

 

Epilepsy

Parkinson’s disease

Alzheimer’s disease

Cerebrovascular disease

Multiple Sclerosis

Others

 

By Distribution Channel:

 

Hospitals Pharmacies

Retail Pharmacies

Online pharmacies

 

By Region:

 

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

 

For More Information, Browse Full Report Here: https://www.coherentmarketinsights.com/ongoing-insight/neurological-disorder-drugs-market-2363

 

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

 

https://www.coherentmarketinsights.com/phase-xs/

 

About Coherent Market Insights:

 

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

 

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Like Reblog Comment
text 2019-03-11 07:16
Congestive Heart Failure Drugs Market Moving Toward 2026 With New Procedures

Congestive heart failure commonly called as heart failure is a medical condition that affects pumping ability of heart muscle. Certain medical conditions such as narrowing of arteries of the heart or high blood pressure gradually makes the heart too weak and stiff to fill and pump efficiently. Some symptoms of heart failure are shortness of breath while lying down or while exerting yourself, weakness, fatigue, swelling in legs, feet and ankles, irregular and rapid heartbeat, decrease in ability to exercise, persistent cough or wheezing with pink or white blood tinged phlegm, increased urination at night, swelling of abdomen, rapid weight gain due to fluid retention, lack of appetite, nausea, difficulty in concentrating, decreased alertness, severe shortness of breath and coughing up pink, and foamy mucus. Click To Read More On Congestive Heart Failure Drugs Market.


There are four types of heart failure left-sided heart failure, right-sided heart failure, systolic heart failure and diastolic heart failure. Risk factors that can cause heart failure are high blood pressure, coronary artery disease, diabetes, sleep apnea, obesity, virus, alcohol use, hypertension and irregular heartbeat. Lifestyle changes can help in prevention of heart failure by reducing and managing stress, maintaining a healthy weight, eating healthy food, staying physically fit and active, controlling blood pressure, and diabetes.


Congestive Heart Failure Drugs Market Drivers:-


Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these drugs are used to treat congestive heart failure. Tolvaptan sponsored by Otsuka pharmaceuticals Co., Ltd was in phase 3 clinical trials in 2016, this drug is indicated for treatment of heart failure in children.


Approval of new drugs from Food and Drug Administration (FDA) is also expected to fuel growth of the congestive heart failure drugs market. In 2016, FDA approved Byvalson by Allergan an Ireland-based company, this drug is used for treatment of hypertension. In 2015, FDA approved Corlanor (ivabradine) by Amgen Inc. a U.S.-based company, this drug treats chronic heart failure. Furthermore, increasing number of geriatric population, unhealthy lifestyle, and increasing awareness regarding treatment of chronic disorders are driving the congestive heart failure drugs market growth.

Low awareness and diagnosis rate for the disease such as hypertension which is major cause of heart failure is primary restraint in global congestive heart failure drugs market. According to a study published in NCBI in 2013, only 49% of patients suffering from hypertension were aware of the diagnosis in high-income countries, and this percentage (i.e. 40.8%) was even lower in low-income countries.


Congestive Heart Failure Drugs Market Key Players:-


Key players operating in congestive heart failure drugs market include Amgen Inc, Novartis AG, Astra Zeneca Plc., Bayer AG, Gilead Sciences Inc, Glaxo Smith Kline, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.


Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/1839


Congestive Heart Failure Drugs Market Regional Analysis:-


North America is expected to hold dominant position in congestive heart failure drugs market due to new product launches and mergers and acquisitions. For instance, in 2015, Amgen Inc. a U.S.-based company acquired Dezima Pharma, a Netherlands based company to expand its cardiovascular drug portfolio by adding cholesterol lowering drug TA-8995 to its portfolio. TA-8995 is a cholesterol lowering drug. Moreover, Europe congestive heart failure drugs market is expected to witness significant growth due to launch of new drugs to treat chronic diseases, which prevent heart failures. For instance, Novartis AG launched a drug named Entresto in 2016, in UK. Entresto is used to treat heart failure with minimum ejection fraction (measurement of percentage of blood leaving heart each time it contracts), it is an angiotensin receptor-neprilysin inhibitor.


Moreover, high prevalence of cardiovascular diseases in Asia Pacific is expected to support the growth of congestive heart failure drugs market in this region. According to a study conducted by All India Institute of Medical Science (AIIMS) and Indian Council of Medical Research (ICMR) in 2016, India’s younger population i.e. below 30 years of age are at a higher risk of developing cardiovascular diseases due to unhealthy lifestyle, alcohol consumption, and tobacco consumption,.


About Coherent Market Insights:


Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us:


Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Like Reblog Comment
text 2019-03-09 09:35
Vitiligo Drugs Market 2018 Expected Vast Growth By 2026 Including Freelancers, Intake, Trials & Forecast By Application, Technologies

Vitiligo is a skin condition characterized by white patches on the skin. It is also known as skin depigmentation. In skin depigmentation, the skin's pigment-making cells known as melanocytes are lost or destroyed, which result into patches. The patches of affected skin appear white and usually have sharp margins. In most of the cases, the patches emerge on the skin, which is more exposed to sunlight. Although the disease can occur at any age, it is more observed in the mid-twenties. Although the disease does not affect the physical health of a person, it creates concerns about physical appearance and ethical identity of the person. The exact cause of Vitiligo is not known. It is mostly observed in people with family history of autoimmune disease. Vitiligo is classified into two types: segmental and non-segmental. In segmental vitiligo, only one side of body is affected by skin depigmentation. In non-segmental vitiligo, both sides of body are affected by skin depigmentation and the affected area of the skin expands with time. In general, non-segmental vitiligo is more common than segmental vitiligo.

 

Request For a Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/2447

 

Vitiligo Drugs Market Drivers

Vitiligo drugs market is expected to witness significant growth, owing to development of new therapies for vitiligo. For instance, in Feb 2018, researchers at Yale University School of Medicine discovered a new therapy for the treatment of vitiligo. The therapy can aid in returning the color of depigmented skin due to vitiligo. The new combination therapy includes oral medication of Xeljanz (tofacitinib) and ultraviolet-B light therapy. Xeljanz is used in the treatment of rheumatoid arthritis and ultraviolet B (UVB) light therapy is an effective treatment for psoriasis. UVB penetrates the skin and slows the growth of affected skin cells.

Moreover, increasing pipeline studies to develop new drugs for the treatment of vitiligo is expected to drive vitiligo drugs market growth. For instance, in December 2016, Nicolaus Copernicus University initiated the phase 1 and phase 2 clinical trial for Atorvastatin calcium salt and Simvastatin-acid sodium salt. The study has been initiated for the evaluation of vitiligous lesions repigmentation after the administration of Atorvastatin calcium salt and Simvastatin-acid sodium salt in patients with active vitiligo. The study is estimated to complete by April 2019.

However, adoption of unlicensed medication may restraint the vitiligo drugs market growth. Topical Calcineurin inhibitors (Tacrolimus and Pimecrolimus) used for treating vitiligo are unlicensed medicines. Prescription of unlicensed medicines for the treatment of vitiligo is attributed to the assumption that these medicine are more effective and offer some benefits in the treatment and show lesser side effect unlike corticosteroids that cause thinning of the skin.

Vitiligo Drugs Market - Taxonomy

By Drugs Class

  • Calcineurin Inhibitors

  • Corticosteroids

  • Immunomodulator

  • Psoralens

By Route of Administration

  • Oral

  • Topical

Vitiligo Drugs Market- Regional Analysis

On the basis of region, the global vitiligo drugs market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Increasing prevalence of vitiligo in North America is expected to boost the vitiligo drug market growth during the forecast period. For instance, according to American Academy of Dermatology, in November 2013, over 150,000 people in the U.S. across all age were treated for vitiligo. The overall cost incurred was over US$ 328 per patient and total medical cost was valued at US$ 49 million.

Asia Pacific is expected to witness significant growth in the vitiligo drugs market, owing to presence of major players in this region and launch of new products. For instance, in 2014, Dr. Reddy’s Laboratories, an India-based multinational pharmaceutical company, launched Melgain lotion to treat vitiligo in partnership with Issar Pharmaceuticals Pvt Ltd. Under the partnership, Issar Pharmaceuticals was tasked to manufacture the product and Dr. Reddy’s Laboratories for its commercialization.

Key players operating in the global vitiligo drugs market include, AXIM Biotechnologies, Dr. Reddy’s Laboratories, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals, Glenmark Pharmaceuticals, and Galderma laboratories (Nestlé Skin Health).

 

Click To Read More On Vitiligo Drugs Market

 

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at sales@coherentmarketinsights.com

 

https://www.coherentmarketinsights.com/phase-xs/

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

More posts
Your Dashboard view:
Need help?